Dechert LLP
Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
The present disclosure relates to Oxime-Substituted Quinoxaline-Type Piperidine Compounds, such as those of Formula (I):and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R20, R21, Q, Y1, Z, A, B, and a are as defined herein; compositions comprising an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound.
Shionogi & Co., Ltd. Purdue Pharma L.P.
C A A C A C A A A C A
C07D A61P A61P C07D A61K C07D A61P A61P A61K C07D A61P
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Xiaoming Jeffrey Michael Naoki Tatsuhiko
Zhou Marra Tsuno Ueno